<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of proposed pathogenic mechanisms in antiphospholipid syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of proposed pathogenic mechanisms in antiphospholipid syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of proposed pathogenic mechanisms in antiphospholipid syndrome</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Proposed mechanism</td> <td class="subtitle1">In vitro evidence</td> <td class="subtitle1">Animal studies</td> <td class="subtitle1">Clinical studies</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Cellular activation</td> </tr> <tr> <td class="indent1">Endothelial cells</td> <td>aPL activate endothelial cells and induce expression of TF and adhesion <span style="white-space: nowrap;">molecules<sup>[1,2]</sup></span></td> <td>Blocking E-selectin, P-selectin, VCAM-1, or ICAM-1 protects against aPL-induced venous <span style="white-space: nowrap;">thrombosis<sup>[3,4]</sup></span></td> <td>High levels of circulating endothelial cell-derived microparticles are present in patients with <span style="white-space: nowrap;">APS<sup>[5]</sup></span></td> </tr> <tr> <td class="indent1">Monocytes</td> <td>aPL activate monocytes to express TF and proinflammatory <span style="white-space: nowrap;">cytokines<sup>[6-12]</sup></span></td> <td> </td> <td>Monocytes from patients with APS express higher levels of <span style="white-space: nowrap;">TF<sup>[13-15]</sup></span>; there are increased monocyte-derived microparticles in patients with <span style="white-space: nowrap;">APS<sup>[16,17]</sup></span></td> </tr> <tr> <td class="indent1">Neutrophils</td> <td>aPL activate neutrophils to express TF and release <span style="white-space: nowrap;">NETs<sup>[18,19]</sup></span></td> <td>Deoxyribonuclease or neutrophil depletion reduce aPL-induced venous <span style="white-space: nowrap;">thrombosis<sup>[20,21]</sup></span></td> <td>The concentration of circulating NETs is increased in patients with <span style="white-space: nowrap;">APS<sup>[19]</sup></span></td> </tr> <tr> <td class="indent1">Platelets</td> <td>aPL induce platelet activation and <span style="white-space: nowrap;">adhesion<sup>[22,23]</sup></span></td> <td>Platelet recruitment to activated endothelium is required for thrombus extension in the <span style="white-space: nowrap;">microcirculation<sup>[24]</sup></span></td> <td>Increased platelet-leukocyte aggregates and platelet-derived microparticles are present in the blood of patients with <span style="white-space: nowrap;">APS<sup>[5,26]</sup></span></td> </tr> <tr> <td class="subtitle2_left" colspan="4">Interactions with coagulation and fibrinolytic systems</td> </tr> <tr> <td class="indent1">Inhibition of natural anticoagulant mechanisms</td> <td>aPL inhibit the activities of protein C and <span style="white-space: nowrap;">antithrombin<sup>[26-31]</sup></span></td> <td> </td> <td>Patients with APS have autoantibodies against factor IXa and factor Xa that interfere with their inactivation by <span style="white-space: nowrap;">antithrombin<sup>[32,33]</sup></span></td> </tr> <tr> <td class="indent1">Inhibition of fibrinolysis</td> <td>aPL inhibit tPA-mediated plasminogen activation and <span style="white-space: nowrap;">fibrinolysis<sup>[34]</sup></span></td> <td> </td> <td>Patients with APS have autoantibodies against tPA and <span style="white-space: nowrap;">plasmin<sup>[35,36]</sup></span></td> </tr> <tr> <td class="indent1">Factor XI</td> <td>aPL enhance the conversion of factor XI to XIa upon treatment with the activators PDI or <span style="white-space: nowrap;">thioredoxin<sup>[37]</sup></span></td> <td>Factor XIa is required for pathologic thrombus formation; PDI inhibitors attenuate thrombus formation in <span style="white-space: nowrap;">mice<sup>[38]</sup></span></td> <td>Patients with APS have elevated levels of the free thiol form of factor <span style="white-space: nowrap;">XI<sup>[37]</sup></span></td> </tr> <tr> <td class="indent1">Disruption of annexin A5</td> <td>Monoclonal aPL disrupt the annexin A5 shield on phospholipid bilayers in vitro; hydroxychloroquine stabilizes the annexin A5 <span style="white-space: nowrap;">shield<sup>[39,40]</sup></span></td> <td>Hydroxychloroquine reduces thrombosis in <span style="white-space: nowrap;">mice<sup>[41]</sup></span></td> <td>Hydroxychloroquine decreases thrombosis in patients with SLE (with or without <span style="white-space: nowrap;">apL)<sup>[42]</sup></span></td> </tr> <tr> <td class="subtitle2_left" colspan="4">Other mechanisms</td> </tr> <tr> <td class="indent1">Complement activation</td> <td>Anti-beta2GPI antibodies induce C5b-9 deposition and complement-mediated cell <span style="white-space: nowrap;">death<sup>[43]</sup></span></td> <td>aPL-induced thrombosis and fetal loss are attenuated in C3-, C5-, and C6-deficient mice, as well as in the presence of complement <span style="white-space: nowrap;">inhibitors<sup>[44-48]</sup></span></td> <td>Sera from patients with APS demonstrate higher than normal complement activation in a functional assay; patients with APS have higher levels of circulating C3a, C5b-9, and <span style="white-space: nowrap;">Bb<sup>[49-51]</sup></span></td> </tr> <tr> <td class="indent1">Trophoblast dysfunction</td> <td>Anti-beta2GPI antibodies interfere with trophoblast proliferation, invasiveness, secretion of HCG, production of angiogenic factors, and <span style="white-space: nowrap;">syncytialization<sup>[52-55]</sup></span></td> <td> </td> <td>A lack of well-developed vasculosyncytial membranes in the placenta of aPL-positive patients limits gas and nutrient exchange in the third <span style="white-space: nowrap;">trimester<sup>[56]</sup></span></td> </tr> <tr> <td class="indent1">mTOR activation</td> <td>In cultured endothelial cells, aPL stimulate mTOR through the PI3K-AKT <span style="white-space: nowrap;">pathway<sup>[57]</sup></span></td> <td> </td> <td>In aPL-associated nephropathy, the vascular endothelium displays markers of mTOR activation; sirolimus prevents recurrence of vasculopathy after kidney <span style="white-space: nowrap;">transplant<sup>[57]</sup></span></td> </tr> </tbody></table></div><div class="graphic_footnotes">aPL: antiphospholipid antibodies; TF: tissue factor; VCAM-1: vascular cell adhesion molecule 1; ICAM-1: intercellular adhesion molecule 1; APS: antiphospholipid syndrome; NETs: neutrophil extracellular traps; tPA: tissue plasminogen activator; PDI: protein disulfide isomerase; SLE: systemic lupus erythematosus; anti-beta2GPI: anti-beta2 glycoprotein I; HCG: human chorionic gonadotrophin; mTOR: mammalian/mechanistic target of rapamycin.</div><div class="graphic_reference">References:

<ol>
<li>Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211.</li>
<li>Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997; 40:551.</li>
<li>Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88:245.</li>
<li>Espinola RG, Liu X, Colden-Stanfield M, et al. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003; 1:843.</li>
<li>Chaturvedi S, Cockrell E, Espinola R, et al. Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. Thromb Res 2015; 135:102.</li>
<li>Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153:1328.</li>
<li>Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79:276.</li>
<li>Reverter JC, Tàssies D, Font J, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41:1420.</li>
<li>Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104:2353.</li>
<li>Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56:2687.</li>
<li>Xie H, Zhou H, Wang H, et al. Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol 2013; 53:246.</li>
<li>Müller-Calleja N, Köhler A, Siebald B, et al. Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. Thromb Haemost 2015; 113:1071.</li>
<li>Cuadrado MJ, López-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40:834.</li>
<li>Dobado-Berrios PM, López-Pedrera C, Velasco F, et al. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82:1578.</li>
<li>López-Pedrera C, Buendía P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54:301.</li>
<li>Nagahama M, Nomura S, Kanazawa S, et al. Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome. Autoimmunity 2003; 36:125.</li>
<li>Vikerfors A, Mobarrez F, Bremme K, et al. Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus 2012; 21:802.</li>
<li>Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177:4794.</li>
<li>Yalavarthi S, Gould TJ, Rao AN, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol 2015; 67:2990.</li>
<li>Meng H, Yalavarthi S, Kanthi Y, et al. In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. Arthritis Rheumatol 2017; 69:655.</li>
<li>Ali RA, Gandhi AA, Meng H, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Nat Commun 2019; 10:1916.</li>
<li>Pennings MT, Derksen RH, van Lummel M, et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 2007; 5:369.</li>
<li>Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50:2911.</li>
<li>Proulle V, Furie RA, Merrill-Skoloff G, et al. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014; 124:611.</li>
<li>Joseph JE, Harrison P, Mackie IJ, et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115:451.</li>
<li>Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74:2426.</li>
<li>Wahl D, Membre A, Perret-Guillaume C, et al. Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system. Curr Rheumatol Rep 2009; 11:77.</li>
<li>Rossetto V, Spiezia L, Franz F, et al. The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. Am J Hematol 2009; 84:594.</li>
<li>Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81:2618.</li>
<li>Borrell M, Sala N, de Castellarnau C, et al. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68:268.</li>
<li>Shibata S, Harpel PC, Gharavi A, et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83:2532.</li>
<li>Yang YH, Chien D, Wu M, et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009; 182:1674.</li>
<li>Yang YH, Hwang KK, FitzGerald J, et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol 2006; 177:8219.</li>
<li>Bu C, Gao L, Xie W, et al. beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum 2009; 60:559.</li>
<li>Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103:2121.</li>
<li>Yang CD, Hwang KK, Yan W, et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172:5765.</li>
<li>Giannakopoulos B, Gao L, Qi M, et al. Factor XI is a substrate for oxidoreductases: enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis. J Autoimmun 2012; 39:121.</li>
<li>Jasuja R, Passam FH, Kennedy DR, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 2012; 122:2104.</li>
<li>Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163:1193.</li>
<li>Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112:1687.</li>
<li>Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96:4380.</li>
<li>Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011; 13:77.</li>
<li>Chaturvedi S, Braunstein EM, Yuan X, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020; 135:239.</li>
<li>Carrera-Marín A, Romay-Penabad Z, Papalardo E, et al. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus 2012; 21:1497.</li>
<li>Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106:2340.</li>
<li>Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52:2120.</li>
<li>Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211.</li>
<li>Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644.</li>
<li>Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992; 10:455.</li>
<li>Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009; 68:1030.</li>
<li>Breen KA, Seed P, Parmar K, et al. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012; 107:423.</li>
<li>Di Simone N, Meroni PL, de Papa N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43:140.</li>
<li>Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352:1037.</li>
<li>Carroll TY, Mulla MJ, Han CS, et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol 2011; 66:286.</li>
<li>Marchetti T, Ruffatti A, Wuillemin C, et al. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost 2014; 12:910.</li>
<li>Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimmun Rev 2015; 14:446.</li>
<li>Canaud G, Terzi F. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371:1554.</li>
</ol></div><div id="graphicVersion">Graphic 132560 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
